The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium
P

2019 Update on Salivary Gland Carcinoma: Anti-HER2 w/o or w/Chemo Docetaxel Is Highly Active for Salivary Duct, Levatinib As Palliative for Recurrent/Metastatic Adenoid Cystic Carcinoma

By 2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium FEATURING Prakash Neupane
By 2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium FEATURING Prakash Neupane
30 views
November 12, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
2019 Lung Cancer and Head & Neck Cancer Symposium
08:12
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Understanding the Distinction of HPV-Mediated (p16+) Oropharynx Canc…

Feat. G. Gan
12:23
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

De-Escalation of HPV-Mediated (p16+) Oropharynx Cancer Treatment: Ra…

Feat. G. Gan
10:27
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

De-Escalation of HPV-Mediated (p16+) Oropharynx Cancer Treatment: TO…

Feat. G. Gan
19:34
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Evaluation and Managing Options of the Adult Neck Mass in the Era of…

Feat. A. Bur
06:51
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on the HPV+ Oropharynx Carcinoma: Cisplatin and Concurre…

Feat. P. Neupane
06:20
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Locally Advanced Nasopharyngeal Cancer: Induction Che…

Feat. P. Neupane
08:21
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Recurrent/Metastatic Head&Neck Squamous Cell Carc…

Feat. P. Neupane
12:55
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

2019 Update on Salivary Gland Carcinoma: Anti-HER2 w/o or w/Chemo Do…

Feat. P. Neupane
17:19
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti…

Feat. D. Gibbons
10:16
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Immunotherapy in Advanced NSCLC: Difficulties With Biomarkers Develo…

Feat. D. Gibbons
13:33
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Checkpoint Inhibitors in Stage III NSCLC (Pacific Trial Regimen) / B…

Feat. D. Gibbons
17:11
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

Microbiome as a Predictive Ecosystem for Immunotherapy in NSCLC Can …

Feat. J. Zhang
12:42
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New KRAS G12C / MET Exon 14 TKI’s for Advanced NSCLC: Favorable Safe…

Feat. C. Huang
22:41
2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / …

Feat. C. Huang